View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 19, 2020updated 12 Jul 2022 11:44am

Seattle Genetics initiates trial of SEA-TGT for solid tumours

Seattle Genetics has dosed the first patient in a Phase I trial SEA-TGT, an anti-TIGIT antibody used for the treatment of patients with solid tumours and lymphomas.

Seattle Genetics has dosed the first patient in a Phase I trial SEA-TGT, an anti-TIGIT antibody used for the treatment of patients with solid tumours and lymphomas.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The nonfucosylated human IgG1 antibody SEA-TGT uses the company’s Sugar Engineered Antibody (SEA) technology.

The Phase I trial will evaluate the safety and anti-tumour activity of SEA-TGT as a single agent and as in combination with the anti-PD-1 antibody, pembrolizumab. It is currently open in multiple sites in the US.

It is expected to enroll about 111 participants and will evaluate the antibody in advanced solid tumours and lymphomas, including non-small cell lung cancer, gastric carcinoma, Hodgkin and selected non-Hodgkin lymphomas.

Based on preclinical data, SEA-TGT, which is also known as SGN-TGT, has improved effector function enabled by the company’s SEA technology.

Seattle Genetics initiated a Phase I clinical trial evaluating investigational agent SGN-B6A, which is also currently open in multiple sites in the US, and is expected to enrol about 235 participants.

SGN-B6A is an antibody-drug conjugate (ADC ) targeting integrin beta-6 that is overexpressed in numerous solid tumours. It has been demonstrated to be a negative prognostic indicator across a diverse range of cancers.

This study will evaluate SGN-B6A in solid tumours, including non-small cell lung cancer, head and neck squamous cell cancer, breast, esophageal, ovarian, bladder, cervical and gastric cancers.

Seattle Genetics chief medical officer Roger Dansey said: “We believe that anti-TIGIT antibodies may have an important therapeutic role in the evolving immuno-oncology landscape.

“SEA-TGT utilises our novel SEA technology, which in preclinical research has demonstrated enhanced effector function that potentially differentiates it from other TIGIT antibodies in the clinic.

“The initiation of clinical trials for both SEA-TGT and the ADC , SGN-B6A, underscore our commitment to advancing novel drug candidates from our pipeline into clinical testing.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena